The Foundation Fighting Blindness is the world’s leading private funding source for research to prevent, treat, and cure retinal degenerative diseases. Many of the trials listed below were made possible by Foundation support.

Genetic Technologies

GENE THERAPIES (GENE TARGET)

Disease/Condition Company Clinical Trial Phase
AMD-dry, GA (RORA) Ocugen Phase 3
AMD-dry, GA (CFH) Perceive Bio Phase 1/2
AMD-dry, GA (CR1)  Complement Tx  Phase 1/2
Bardet-Biedl Syndrome (BBS1) 

Axovia

Phase 1

Batten disease (CLN2) 

Tern Therapeutics 

Phase 1/2

Batten disease (CLN5) Neurogene Phase 1/2
BCD (CYP4V2) Shanghai Vitalgen Phase 3
Best disease (BEST1) Opus Genetics Phase 1/2
LCA (GUCY2D) Atsena Phase 1/2
LCA (LCA5) Opus Genetics Phase 1/2/3
LCA, RP (RDH12) Peking Union Medical College Hosp Phase 1
RLBP1 Retinal Dystrophy (RLBP1)  Peking Union Medical College Hosp Phase 1
RP (CNGA1) VeonGen Phase 1
RP (NR2E3, gene agnostic) Ocugen Phase 3
RP (RdCVF, gene agnostic) SparingVision Phase 1/2
Stargardt disease (RORA) Ocugen Phase 2/3
Stargardt disease (ABCA4) Splice Bio Phase 1/2
Stargardt disease (ABCA4) VeonGen Phase 1/2
Stargardt disease (ABCA4) AAVantgarde Phase 1/2
Usher syndrome (MYO7A) AAVantgarde Phase 1/2
X-linked Retinoschisis (RS1) Atsena Phase 1/2/3
X-linked RP (RPGR) Beacon Phase 2/3
X-linked RP (RPGR) MeiraGTx Phase 3

RNA THERAPIES (MECHANISM)

Disease/Condition Company Clinical Trial Phase
AMD-dry, GA (siRNA targeting CFB)  ADARx  Phase 2
AMD-dry, GA (RNAi for undisclosed target) Genentech  Phase 2
LCA10 (AON targeting CEP290 IVS26) Sepul Bio Phase 3
RP11 (AON targeting CNOT3) PYC Phase 1/2
RP, Usher (AON targeting USH2A exon 13) Sepul Bio Phase 2
Stargardt disease (ABCA4 RNA editing) Ascidian Phase 1/2
Stargardt disease (RNAi targeting RBP4) City Therapeutics  Phase 1

Novel Medical Therapies

SMALL MOLECULES, PROTEINS (INVESTIGATIONAL PRODUCT) 

Disease/Condition Company Clinical Trial Phase
AMD-dry, GA (Gildeuretinol) Alkeus Phase 2/3
AMD-dry, GA (ANX007) Annexon Phase 3
AMD-dry, GA (Tinlarebant) Belite Bio Phase 3
AMD-dry, GA (BRX001) Biojiva Phase 1/2
AMD-dry, GA (BI 771716) Boehringer Ingelheim Phase 2
AMD-dry, GA (BI 1584862) Boehringer Ingelheim Phase 2
AMD-dry, GA (ONL1204) ONL Therapeutics Phase 2
AMD-dry, GA (Elamipretide) Stealth Bio Phase 3
AMD-dry, GA (Pozelimab, Cemdisiran) Regeneron Phase 3
AMD-dry, GA (FWY003)  Novartis  Phase 2
RP, CHM (KIO-301) Kiora Phase 2
RP (Disulfiram) University of Washington Phase 1/2
RP (NAC) Johns Hopkins University Phase 3
RP-RHO (OCT-980)  Octant Bio  Phase 1/2
RP (Pitavastatin nanoparticles)  Kyushu University  Phase 1
Stargardt disease (Gildeuretinol) Alkeus Phase 2
Stargardt disease (Tinlarebant) Belite Bio Phase 2/3
Stargardt disease (Metformin) NEI Phase 1/2
Usher syndrome (NACA) Nacuity Phase 3
Usher syndrome 3 (BF844) USH III Initiative Phase 1

Restorative Therapies

CELL-BASED THERAPIES (CELL TYPE) 

Disease/Condition Company Clinical Trial Phase
AMD-dry, GA (RPE) Astellas Phase 1
AMD-dry, GA (RPE) Eyestem Phase 1/2
AMD-dry, GA (RPE) Lineage/Genentech Phase 2
AMD-dry, GA (RPE) Luxa Bio Phase 1/2
AMD-dry, GA (RPE) NEI Phase 1/2
AMD-dry, GA (RPE) Regenerative Patch Phase 2
AMD-dry, GA, Stargardt (RPE)  Cellio  Phase 1
RP, Usher, CRD (retinal precursors) BlueRock Phase 1/2
RP, Usher (retinal progenitors) jCyte Phase 2b
RP (iPSC retinal sheets) Sumitomo Pharma  Phase 1/2
RP (RPE)  Centre D'Etude Des Cellules Souches  Phase 1/2

OPTOGENTIC THERAPIES (CELL TARGET) 

Disease/Condition Company Clinical Trial Phase
AMD-dry, GA (RGCs) Bionic Sight Phase 1/2
RP (RGCs) Zhongmou Therapeutics Phase 1
RP (Cones) SparingVision Phase 1/2
RP (BCs) 

Restore Vision 

Phase 1/2
RP (RGCs) Bionic Sight Phase 1/2
RP (RGCs) GenSight Phase 1/2
RP (BCs) Nanoscope Phase 2
RP, CHM (RGCs) Ray Therapeutics Phase 1
Stargardt disease (BCs) Nanoscope Phase 2
Stargardt disease (BCs) Ray Therapeutics Phase 1/2

RETINAL PROSTHETICS (DEVICE LOCATION)

Disease/Condition Company Clinical Trial Phase
IRDs, Stargardt, RP (PRIMA, Subretinal) Science Corporation  Pilot Phase

Approved Therapies

Disease/Condition Company Clinical Trial Phase
AMD-dry, GA (SYFOVRE, C3 inhibitor) Apellis Approved
AMD-dry, GA (IZERVAY, C5 inhibitor) Astellas Approved
LCA (LUXTURNA, RPE65) Spark/Roche Approved
AMD-dry, GA (PRIMA, retinal prosthetic)  Science Corp  Approved in European Union

Note: This is not a complete list. Some trials listed may have been paused and/or the sponsors are seeking partners to continue their trials. To learn more about additional clinical trials underway for inherited retinal diseases and geographic atrophy, visit www.ClinicalTrials.gov. The site lists detailed information about many relevant trials, including eligibility criteria and sponsor contact information.